Brief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
08/10/2026 22:21
BRIEF-Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout Oct 8 (Reuters) - XORTX Therapeutics Inc XRTX.O:
XORTX OUTLINES ANTICIPATED HEALTH CANADA CLINICAL TRIAL APPLICATION FOR XRX-026 FOR GOUT
XORTX THERAPEUTICS - RECEIVES INCREASED INQUIRIES FROM POTENTIAL COMMERCIALIZATION PARTNERS FOR XRX-026
XORTX THERAPEUTICS - FIRST PART OF XRX-OXY-102 STUDY IN CANADA EXPECTED TO ACCELERATE NDA FILING WITH FDA
XORTX THERAPEUTICS - APPLICATION OUTLINES PLAN TO ADVANCE XRX-026 TOWARD REGULATORY APPROVAL IN CANADA AND NDA FILING WITH FDA
Source text: ID:nGNXbTxVC6
Further company coverage: XRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering